termsTerm
Endometrial cancer molecular classes (POLEmut, MMRd, p53abn, NSMP)
Four groups defined by a few tests that predict outcome better than the microscope: POLE-mutated (excellent), mismatch-repair deficient, p53-abnormal (worst), and 'no specific profile'.
From TCGA (Nature 2013) via the ProMisE classifier (Talhouk 2015) into the WHO 2020 classification and ESGO/ESTRO/ESP 2021 guidelines. POLE-ultramutated (~7%) almost never relapses and may need no adjuvant therapy; MMRd (~25-30%) responds to immunotherapy; p53abn (~15%; includes most serous) benefits from chemotherapy (PORTEC-3) and often carries HER2 amplification; NSMP (~50%) is heterogeneous, with L1CAM and ER status refining risk. Molecular-class-directed adjuvant trials (RAINBO programme, PORTEC-4a) are ongoing.
Cancer biology: what this kind of term is about · animated schematic, not to scale
Category
Cancer biology